StockData
BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc. (BTAIQ) stock

BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 3/30
$0.03−0.00 (-13.49%)

Close on Oct 19, 2026Market cap $757.50KP/E –Yield –

BioXcel Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

BioXcel Therapeutics's ebitda for the twelve months ending Mar 31, 2022 was -$111.73M. For fiscal 2021 it was -$106.64M. The highest annual figure on record is -$4.54M in fiscal 2017.

Annual ebitda

PeriodPeriod endValueChange
FY2021Dec 31, 2021-$106.64M–
FY2020Dec 31, 2020-$82.11M–
FY2019Dec 31, 2019-$33.45M–
FY2018Dec 31, 2018-$19.95M–
FY2017Dec 31, 2017-$4.54M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2022Mar 31, 2022-$31.40M–
Q4 FY2021Dec 31, 2021-$26.06M–
Q3 FY2021Sep 30, 2021-$26.74M–
Q2 FY2021Jun 30, 2021-$27.53M–
Q1 FY2021Mar 31, 2021-$26.31M–
Q4 FY2020Dec 31, 2020-$21.05M–
Q3 FY2020Sep 30, 2020-$24.72M–
Q2 FY2020Jun 30, 2020-$21.39M–
Q1 FY2020Mar 31, 2020-$14.95M–
Q4 FY2019Dec 31, 2019-$8.48M–
Q3 FY2019Sep 30, 2019-$9.04M–
Q2 FY2019Jun 30, 2019-$8.55M–
Q1 FY2019Mar 31, 2019-$7.38M–
Q4 FY2018Dec 31, 2018-$7.31M–
Q3 FY2018Sep 30, 2018-$5.11M–
Q4 FY2017Dec 31, 2017-$2.53M–
Q1 FY2017Mar 31, 2017-$528.00K–

More BioXcel Therapeutics figures

See a number that looks wrong?